Furthermore, treatment with 0.4 μM anlotinib (a concentration at which the cell viability was greater than 90%) significantly potentiated the efficacy of chemotherapeutic agents that are known PGP1 substrates in the multidrug-resistant U2OSR2 and KHOSR2 osteosarcoma cell lines. The gene discussed is CD44; the disease is osteosarcoma.